辛伐他汀在急性冠脉综合征患者中的早期应用  

Application of simvastatin in patients with acute coronary syndrome in early stage

作　　者：杨彬[1] 

机构地区：[1]广东医学院附属医院,广东湛江524001

出　　处：《实用医技杂志》2008年第15期1922-1924,共3页Journal of Practical Medical Techniques

摘　　要：目的:探讨早期应用辛伐他汀对急性冠脉综合征患者的血脂和C反应蛋白影响。方法:68例急性冠脉综合征患者随机分为常规治疗组和辛伐他汀组,常规治疗组予阿司匹林、肝素、硝酸酯类、血管紧张素转换酶抑制剂及β-受体阻滞剂等,不使用其他调脂、抗氧化药物、非类固醇类消炎镇痛药物;辛伐他汀组在常规治疗基础上加用辛伐他汀20mg/d晚餐后服用,疗程8周,治疗前后测量血脂及C反应蛋白并与健康对照组比较。结果:急性冠脉综合征患者C反应蛋白升高,经治疗后均有下降,辛伐他汀组TC及C反应蛋白较常规治疗组下降明显,两组比较有统计学差异,未见有严重不良反应出现。结论:早期应用辛伐他汀可以降低急性冠脉综合征患者的血脂及C反应蛋白水平,具有稳定斑块、抑制炎症等作用,是一有效、安全的治疗手段。Objective To observe the influence of simvastatin on blood lipid and C-reactive protein(CRP) in patients with acute coronary syndrome(ACS).Methods 68 patients were divided into treatment group with simvastatin and control group without simvastatin,The treatment group receive simvastatin 20 mg/d,The blood lipid and C-reactive protein(CRP) were measured before and after the treatment.30 healthy people were measured as healthy control group.Results Patients with ACS had higher levels of CRP than those of healt...

关 键 词：辛伐他汀 急性冠脉综合征 C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]